Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteomics and Stem Cell Therapy in Critical Limb Ischemia
NCT02802852Completed
- Sponsor
- University of Illinois Chicago
- Start
- Jun 2016
- Primary completion
- Mar 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of filgrastim in critical limb ischemia (CLI), sponsored by University of Illinois Chicago. Primary endpoints: Hepatocyte Growth Factor at 30 days, Insulin Growth Factor at 30 days and 20 more. Started Jun 2016; status: completed.
02
Drugs
filgrastim
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02802852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802852.